Revolutionizing type 2 diabetes treatment: personalized approach shows promise in matching patients with optimal glucose-lowering therapies

FHS
August 10, 2023
10:37 am

A personalized therapy selection algorithm for two diabetes type 2 (T2D) treatment drug classes.

Base-Edited CAR-T Product ‘Potent’ in Relapsed Childhood T-Cell ALL

The use of base editing to generate universal off-the-shelf chimeric antigen receptor (CAR) T cells in patients with relapsed T-cell acute lymphoblastic leukemia (ALL) should

June 15, 2023

Renaissance to in-license St Jude’s humanised antibody

Hu14.18 is in development for the treatment of newly diagnosed high-risk neuroblastoma. Credit: Kateryna Kon/Shutterstock.com. Renaissance Pharma has signed an agreement to in-license St Jude

August 1, 2023

Immunic to Participate in Industry and Scientific Conferences in June – Biotech Investments

Issuer: Immunic AG / Key word(s): Conference 28.05.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate

May 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.